Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25653103 | 0.86 | CES2 (0.53) | MAPTPARP1CES2CES1STS | |
| SCHEMBL8588323 | 0.85 | MAPT (0.70) | MAPTPOLBNPC1MAPK1HTT | |
| SCHEMBL4680433 | 0.84 | CYP2C8 (0.59) | MAPTPOLBPARP1CES2CES1 | |
| SCHEMBL4675271 | 0.84 | CYP2C8 (0.59) | MAPTPOLBPARP1CES2CES1 | |
| SCHEMBL4267213 | 0.84 | GAA (0.59) | MAPTPARP1CES2CES1STS | |
| SCHEMBL2702939 | 0.83 | RAB9A (0.56) | MAPTPOLBPARP1CES2CES1 | |
| SCHEMBL29379915 | 0.82 | MAPT (0.66) | MAPTPOLBNPC1MAPK1HTT | |
| SCHEMBL14740763 | 0.82 | MAPT (0.66) | MAPTPOLBNPC1MAPK1HTT | |
| SCHEMBL5188852 | 0.82 | MAPT (0.55) | MAPTPOLBNPC1MAPK1HTT | |
| SCHEMBL30136061 | 0.82 | CES2 (0.62) | MAPTPARP1CES2CES1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | KURA ONCOLOGY INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4720073-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4698173-A1 | TREATMENT OF NON-SMALL CELL LUNG CANCER WITH A COMBINATION OF 3-AMINO-3-(1-METHYL-1H-IMIDAZOL-5-YL)-6-OXA-2(4,6)-QUINOLINA-1,4(1,3)-DIBENZENACYCLOHEXAPHANE-22,44-DICARBONITRILE AND AN EGFR-TKI | Kura Oncology, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12466835-B1 | Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4637769-A1 | METHODS OF TREATING ADVANCED SOLID TUMORS | Kura Oncology, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-119504706-A | Macrocyclic compounds having farnesyl transferase inhibitory activity | 库拉肿瘤学公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024245364-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | KURA ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024220600-A1 | TREATMENT OF NON-SMALL CELL LUNG CANCER WITH A COMBINATION OF 3-AMINO-3-(1-METHYL-1H-IMIDAZOL-5-YL)-6-OXA-2(4,6)-QUINOLINA-1,4(1,3)-DIBENZENACYCLOHEXAPHANE-22,44-DICARBONITRILE AND AN EGFR-TKI | KURA ONCOLOGY, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4441038-A1 | MACROCYCLIC COMPOUNDS HAVING FARNESYLTRANSFERASE INHIBITORY ACTIVITY | Kura Oncology, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240287023-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | KURA ONCOLOGY INC (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024137751-A1 | METHODS OF TREATING ADVANCED SOLID TUMORS | KURA ONCOLOGY, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137751-A1 | METHODS OF TREATING ADVANCED SOLID TUMORS | KURA ONCOLOGY, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
| WO-2023102378-A1 | MACROCYCLIC COMPOUNDS HAVING FARNESYLTRANSFERASE INHIBITORY ACTIVITY | KURA ONCOLOGY, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102378-A1 | MACROCYCLIC COMPOUNDS HAVING FARNESYLTRANSFERASE INHIBITORY ACTIVITY | KURA ONCOLOGY, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | FDPS, PCTP, MTTP | MAPT 2019/4885POLB 4699/4885PARP1 4681/4885 |
| US-12466835-B1 | Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same | FNTA, SF3B1, SF3A1 | MAPT 2911/4885POLB 4681/4885PARP1 3827/4885 |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | FNTA, FDPS, GGPS1 | MAPT 4146/4885POLB 4533/4885PARP1 3715/4885 |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | MAPT 4146/4885POLB 4533/4885PARP1 3715/4885 |
| US-20240287023-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | MAPT 4146/4885POLB 4533/4885PARP1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.